Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMO-103 in advanced high-grade osteosarcoma
NCT06650514Phase 2Recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OMO-103 in osteosarcoma (OS), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Preliminary anti-tumour activity of OMO-103 monotherapy at 16 weeks. Started Dec 2024; status: recruiting.
02
Drugs
OMO-103
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT06650514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650514.